Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan

Kidney and Blood Pressure Research

Volumn 32, Issue 1, 2009, Pages 51-58

  Kaneshiro, Yuki ^a   Ichihara, Atsuhiro ^a   Sakoda, Mariyo ^a   Kurauchi Mito, Asako ^a   Kinouchi, Kenichiro ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Intima media thickness; Pulse wave velocity; Urinary albumin excretion

Indexed keywords

AMLODIPINE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADD ON THERAPY; ADULT; ALBUMINURIA; ARTERY INTIMA; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALBUMINURIA; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CAROTID ARTERIES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TETRAZOLES; THIAZIDES; VALINE;

EID: 61349142469     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205521     Document Type: Article

References (28)

1. Weir MR: Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens 2008;10:4-12.
2. Bakris GL: Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens 2008;10:27-32.
3. Ruilope LM, Zanchetti A: Targeting hypertension with valsartan: lessons learned from the valsartan/HCTZ versus amlodipine in stage II hypertensive patients (VAST) trial. JRAAS 2006;7:S8-S11.
4. Shimosawa T, Gohchi K, Yatomi Y, Fujita T: Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/ hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res 2007;30:831-837.
5. London GM, Cohn JN: Prognostic application of arterial stiffness: task forces. Am J Hypertens 2002;15:754-758.
6. Tsivgoulis G, Vemmos K, Papamichael C, et al: Common carotid artery intima-media thickness and the risk of stroke recurrence. Stroke 2006;37:1913-1916.
7. Olsen MH, Wachtell K, Ibsen H, et al: Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24:775-781.
8. Pontremoli R, Leoncini G, Viazzi F, et al: Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patients: role of microalbuminuria. J Am Soc Nephrol 2006;17:S112-S114.
9. Imai E, Horio M, Iseki K, et al: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007;11:156-163.
10. Niwa Y, Ishimoto K, Kanoh T: Induction of superoxide dismutase in leukocytes by paraquat: correlation with age and possible predictor of longevity. Blood 1990;76:835-841.
11. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T: Fluvastatin prevents development of arterial stiffness in hemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-1517.
12. Ichihara A, Hayashi M, Koura Y, Tada Y, Hirota N, Saruta T: Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 2003;16:959-965.
13. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, et al: Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005;45:866-874.
14. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T: Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005;19:103-109.
15. Sun K, Daimon M, Watanabe S, Komuro I, Masuda Y: The relation of pulse wave velocities measured by oscillometric and tonometric methods and clinical application studies. Jpn J Appl Physiol 2002;32:81-86.
16. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25:359-364.
17. Nandeesha H, Pavithran P, Madanmohan T: Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men. Angiology 2008; epub ahead of print.
18. Yilmaz MI, Sonmez A, Caglar K, et al: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007;12:147-153.
19. Tershakovec AM, Keane WF, Zhang Z, et al: Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care 2008;31:445-447.
20. Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S, Khan BV: Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002;89:686-690.
21. Kedziora-Kornatowska K, Czuczejko J, Szewezyk-Golec K, et al: Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension. Clin Exp Pharmacol Physiol 2006;33:751-756.
22. Ogihara T, Nakao K, Fukui T, et al: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51:393-398.
23. Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
24. Wright JT Jr, Harris-Haywood S, Pressel S, et al: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome. Arch Intern Med 2008;168:207-217.
25. Gress TW, Nieto J, Shahar E, Wofford MR, Brancati FL, Study FtARiC: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-912.
26. Mykkanen L, Kuusisto J, Pyorala K, Laakso M, Haffner SM: Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens 1994;12:1425-1432.
27. Warram JH, Laffel LM, Valsania P, Christlieb AR, Krolewski AS: Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991;151:1350-1356.
28. Zanchetti A, Bond MG, Hennig M, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427.